00:57 , Jan 6, 2017 |  BC Extra  |  Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit partnered...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

BPX-101: Additional Phase I/II data

Additional data from an open-label, dose-escalation, U.S. Phase I/II trial in 12 patients showed that low-, mid- and high-doses of intradermal BPX-101 given every other week in combination with AP1903 for 6 doses produced...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

BPX-101: Interim Phase I/II data

Interim data from a Phase I/II trial in 6 evaluable patients showed that low- and mid-doses of intradermal BPX-101 given every other week in combination with AP1903 for 6 doses produced 4 cases of stable...
07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Disease models CD1-expressing transgenic mouse models of Mycobacterium tuberculosis infection Mice engineered to express human CD1 molecules could serve as a model of tuberculosis to help guide development of...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Clinical News

BP-GMAX-CD1: Phase I/IIa started

Bellicum began an open-label, dose-escalation, U.S. Phase I/IIa trial in 24 patients to evaluate 6 doses of intradermal BP-GMAX-CD1 given weekly or every other week in combination with activating agent AP1903. Ariad granted Bellicum a...
07:00 , Aug 7, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Infectious Disease ...
07:00 , Aug 7, 2008 |  BC Innovations  |  Targets & Mechanisms

Avoiding TB's subversion

Mycobacterium tuberculosis has proven a tough bug to tame, with no effective vaccines on the market to stop the bacterium's spread. Now, a study published in the Proceedings of the National Academy of Sciences describes...
07:00 , Mar 27, 2008 |  BC Innovations  |  Cover Story

Antigens by Special Delivery

DNA vaccines often require high and repeated dosing of antigen, which suggests suboptimal priming of the immune system and results in weak immunogenicity.1 Separate papers in Nature Biotechnology and the Journal of Clinical Investigationnow show...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

Ariad, Bellicum deal

ARIA granted Bellicum a non-exclusive license to Argent cell signaling regulation technology, including the dimerizing compound AP1903, for use in cancer vaccines. ARIA will get an undisclosed equity stake in Bellicum and will be...
07:00 , Sep 11, 2000 |  BC Week In Review  |  Company News

Aquila other research news

AQLA received a $127,989 Phase I SBIR grant from the National Institute of Allergy and Infectious Diseases to develop vaccines to prevent S. aureus infections using AQLA's CD1 antigen presentation immune enhancement technology. Aquila Biopharmaceuticals...